Apogee CEO Michael Henderson at #JPM24 (Brian Benton Photography)

Apogee re­ports Phase 2 win for eczema drug that could chal­lenge Dupix­ent and Ebglyss

Apogee Ther­a­peu­tics said on Mon­day that its atopic der­mati­tis can­di­date, which has the po­ten­tial to of­fer a more con­ve­nient al­ter­na­tive to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.